Published in Vaccine Weekly, August 16th, 2006
The enterovirus 71 (EV-71 or hand, foot, & mouth disease in children) project is one of high commercial significance to Anadis, offering the potential to contribute significant revenue commencing during the 2006/07 financial year. The commencement of the EV-71 hyperimmunization program has occurred as a result of significant and successful interaction between Anadis, Ltd., Australian Quarantine Inspection & Service, and Australian Pesticides & Veterinary Medicines Association whereby both independent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly